Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Mark Lennihan / AP
Medicare's final 2018 hospital payment rule set in stone a spate of policies — ranging from a withdrawn proposal that would have required accrediting bodies to make confidential hospital inspections public to a new (and unpopular) system for calculating hospitals' uncompensated care.
But a handful of other payment policy changes also will go into effect next year, pleasing the various companies and industries that lobbied the Centers for Medicare and Medicaid Services.
Smaller payment cut for heart devices: Medicare proposed updating its payment system based on new medical coding data, and payments for the "other heart assist system implant" reimbursement code would have been slashed by almost 35%. The cut would have especially affected Abiomed, a company that makes heart devices.
Hospitals using that code and Abiomed's heart device are currently paid about $96,000 per treatment, and it would have been reduced to about $63,000. Abiomed lobbied Medicare officials in July to blunt the cut. Medicare agreed, and now the payment will reduced by a lower 19% rate for 2018.
Here are other nuggets embedded within Medicare's final inpatient rule, the first under Department of Health and Human Services secretary (and orthopedic surgeon) Tom Price:
- Big Ankle: Medicare officially will pay more for total ankle replacements. This will benefit ankle surgeons and medical device companies that make ankle implants.
- More on heart devices: Medicare approved add-on payments for two heart valve devices — one made by Edwards Lifesciences and the other by LivaNova. Each hospital case that uses the devices will get an additional $6,100, which could incentivize hospitals to use those devices.
- J&J drug: Hospitals that use Johnson & Johnson's new IV drug, Stelara, for patients with Crohn's disease will receive an add-on payment of $2,400 per case.
- Merck drug: Hospitals that use Merck's new anti-infective drug, Zinplava, for patients with an infection called Clostridium difficile will get an additional $1,900 per case.
- Newspaper notices: Ambulatory surgery centers and clinics will no longer have to put a notice in a print newspaper if they get terminated from the Medicare program, but will still have to alert the public through websites or other media.